Suppr超能文献

通过液滴数字PCR检测初发性小细胞肺癌中临床相关的表皮生长因子受体(EGFR)变异

Detection of clinically-relevant <em>EGFR</em> variations in <em>de novo</em> small cell lung carcinoma by droplet digital PCR.

作者信息

Venkataram Rajesh, Shetty Vijith, Prasad Kishan, Kille Sonam, Srinivas Teerthanath, Chakraborty Anirban

机构信息

Department of Pulmonary Medicine, KS Hegde Medical Academy, Nitte (Deemed to Be University), Mangalore.

Department of Medical Oncology, KS Hegde Medical Academy, Nitte (Deemed to Be University), Mangalore.

出版信息

Monaldi Arch Chest Dis. 2022 Sep 2;93(2). doi: 10.4081/monaldi.2022.2280.

Abstract

Targeted therapy that utilizes tyrosine kinase inhibitors (TKIs), specific to epidermal growth factor receptors (EGFR) has changed the landscape of treatment of non-small cell lung cancer (NSCLC). The success or failure of this approach depends on presence of certain variations in the tyrosine kinase domain of EGFR gene. Generally, patients diagnosed with Small cell lung cancer (SCLC) are considered ineligible for TKI therapy owing to the absence of EGFR variations. . However, there is evidence of these variations being detected in SCLCs, both in de-novo and in transformed SCLCs (TKI-treated adenocarcinomas). Despite the presence of clinically-relevant EGFR variations in SCLCs, the response to TKIs has been inconsistent.  Liquid biopsy is a well-established approach in lung cancer management with proven diagnostic, prognostic and predictive applications. It relies on detection of circulating tumor-derived nucleic acids present in plasma of the patient. In this study, a liquid biopsy approach was utilized to screen 118 consecutive lung cancer patients for four clinically-relevant variations in EGFR gene, which included three activating/sensitizing variations (Ex18 G719S, Ex19del E746-A750 and Ex21 L858R) and one acquired/resistance (Ex20 T790M, de novo) variation by droplet digital PCR, the most advanced third generation PCR technique. As expected, clinically-relevant EGFR variations were found in majority of the non-small cell lung cancer cases. However, among the handful of small cell lung cancer samples screened, sensitizing variations (Ex18 G719S and Ex21 L858R) were seen in almost all of them. Interestingly, Ex20 T790M variation was not detected in any of the cases screened.  The results of our study indicate that EGFR variations are present in SCLCs and highly sensitive liquid biopsy techniques like ddPCR can be effectively utilized for this purpose of screening EGFR variations in such samples.

摘要

利用针对表皮生长因子受体(EGFR)的酪氨酸激酶抑制剂(TKIs)的靶向治疗改变了非小细胞肺癌(NSCLC)的治疗格局。这种治疗方法的成败取决于EGFR基因酪氨酸激酶结构域中某些变异的存在情况。一般来说,被诊断为小细胞肺癌(SCLC)的患者由于不存在EGFR变异,被认为不适合接受TKI治疗。然而,有证据表明在原发性和转化性SCLC(接受TKI治疗的腺癌)中均检测到了这些变异。尽管SCLC中存在临床相关的EGFR变异,但对TKIs的反应并不一致。液体活检是肺癌管理中一种成熟的方法,具有已证实的诊断、预后和预测应用。它依赖于检测患者血浆中存在的循环肿瘤来源核酸。在本研究中,采用液体活检方法,通过最先进的第三代PCR技术——液滴数字PCR,对118例连续的肺癌患者进行EGFR基因四种临床相关变异的筛查,其中包括三种激活/敏感变异(Ex18 G719S、Ex19del E746 - A750和Ex21 L858R)和一种获得性/耐药(Ex20 T790M,原发性)变异。正如预期的那样,在大多数非小细胞肺癌病例中发现了临床相关的EGFR变异。然而,在筛查的少数小细胞肺癌样本中,几乎所有样本都出现了敏感变异(Ex18 G719S和Ex21 L858R)。有趣的是,在所筛查的任何病例中均未检测到Ex20 T790M变异。我们的研究结果表明,SCLC中存在EGFR变异,像液滴数字PCR这样的高灵敏度液体活检技术可有效用于筛查此类样本中的EGFR变异。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验